Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

Sponsor
NanoAlvand
Study ID
NCT07101471
Status
Completed

Conditions

  • Alopecia Areata(AA)
  • Alopecia Totalis/Universalis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.

Study Details

The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia. The main questions are aim to answer: 1. Is Rhofanib® (Tofacitinib) safe in Alopecia? 2. Is Rhofanib® (Tofacitinib) work to treat Alopecia? In this study, there is no comparison group. Participants received Rhofanib® (Tofacitinib) with or without adjuvant prednisolone.

Key Dates

Start date
Aug 4, 2020
Status verified
Aug 2025
Primary completion
Jun 11, 2025
Completion
Jun 11, 2025

Study Design

Enrollment
296 participants (actual)

Arms

  • Arm: Participants received Rhofanib® (Tofacitinib)

Primary Outcome Measure

Safety assessment [ Time Frame: Study period ( Up to 6 months) ]

Related Studies